Engineered Extracellular Vesicles for Extended Plasma Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Extracellular vesicles (EVs) have a short plasma half-life and manufacturing challenges, limiting their clinical application due to rapid uptake in target tissues and difficulties in scaling up production and purification.
Innovation Solution
In vivo production of genetically engineered EVs using a polynucleotide cargo that encodes for a fusion protein, allowing for autologous, patient-specific EV production with extended half-life and improved biodistribution by leveraging the patient's cellular machinery for production and immune tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If EVs are administered systemically, then they can deliver drug cargo across biological barriers, but they are rapidly taken up into target tissues resulting in short plasma half-life
Solution Approach 1:
The invention modifies the surface properties of EVs by engineering specific surface proteins and ligands, changing the physical-chemical parameters of the EV surface to reduce recognition by the reticuloendothelial system and extend circulation half-life while maintaining target delivery capability
Solution Approach 2:
The invention creates composite EV structures with engineered surface compositions, combining multiple protein components and ligands on the EV surface to achieve both extended circulation and efficient target tissue delivery
2Productivity
If EV manufacturing is scaled up for commercial use, then production capacity increases, but purification processes cause changes to the EV surface
Solution Approach 1:
The invention performs preliminary engineering of the EV surface properties during the production phase, incorporating protective surface modifications before purification processes to maintain surface integrity throughout downstream processing
Solution Approach 2:
The invention utilizes the cellular machinery to self-assemble EVs with pre-engineered surface properties, allowing the biological system itself to maintain surface integrity during production and purification without requiring complex external protection measures
Data Source
AI summary
The present invention relates to engineered extracellular vesicles (EVs) as a therapeutic modality for the treatment of various severe diseases. More specifically, the invention relates to a novel approach to manufacturing engineered EVs which extends their half-life and alters their biodistribution, resulting in a novel therapeutic modality able to carry various types of drugs suitable for application in not only genetic diseases but more broadly across essentially all therapeutic areas.